Inactive Instrument

Highlights Revelation Biosciences, Inc. Nasdaq

Equities

REVBU

US76135L2007

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Revelation Biosciences Shares Jump on Positive Results for Investigational Drug Gemini	06-24	MT
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity	06-24	CI
Revelation Biosciences, Inc. Has Completed Dosing of Its First in Human Phase 1 Clinical Study of Gemini	06-13	CI
Revelation Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Revelation Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-22	CI
Revelation Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-22	CI
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini	03-04	CI
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Thursday on Unchanged Fed Rate, Upcoming Earnings	02-01	MT
Revelation Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Revelation Biosciences Inc. Announces Data from Recent Preclinical Studies of the Gemini Formulation Demonstrates Its Therapeutic Potential as A Preventative Therapy Across Multiple Indications Including Infection and Acute Kidney Injury	12/10/23	CI
Revelation Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
Revelation Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	22/05/23	CI
Revelation Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI
Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300	07/02/23	CI
Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition in Preclinical Model	18/11/22	CI
Earnings Flash (REVB) REVELATION BIOSCIENCES Reports Q3 Loss $-0.06	10/11/22	MT
Revelation Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22	CI
Revelation Biosciences Inc. Announces Positive Results in Preclinical Model of Acute and Chronic Kidney Disease	25/10/22	CI
Revelation Biosciences Signs Licensing Deal With Vanderbilt University; Shares Jump	06/10/22	MT
Revelation Biosciences Inc. and Vanderbilt University Enter Exclusive Worldwide License Agreement	06/10/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Revelation Biosciences, Inc. Nasdaq

Equities

REVBU

US76135L2007

Highlights

Filters